GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Simulations Plus Inc.
Simulations Plus provides modeling software used in pharmaceutical R&D to predict drug properties. Its stock price reflects the growing adoption of computer modeling to speed up and reduce the cost of drug development.
Share prices of companies in the market segment - It med
Simulations Plus (SLP) develops modeling and simulation software used by pharmaceutical companies to accelerate drug research and development. We classify it as "Medical IT." The chart below highlights the general trends in the technology sector transforming modern pharmacology.
Broad Market Index - GURU.Markets
Simulations Plus provides modeling and simulation software used by pharmaceutical companies to accelerate drug development. As a component of the GURU.Markets index, it represents the healthcare IT sector. The chart below represents the entire market. See how Simulations Plus shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
SLP - Daily change in the company's share price Simulations Plus Inc.
The daily price change of Simulations Plus, a developer of pharmaceutical simulation software, is a measure of its sensitivity to R&D spending. Change_co reflects the stability inherent in this niche market. This metric is important for analyzing companies in the medical IT sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - It med
Simulations Plus, Inc. is a developer of pharmaceutical simulation software. This chart shows the average daily volatility of the tech sector. Compared to the dynamics of SLPs, whose revenue depends on pharmaceutical companies' R&D budgets, it becomes a barometer of innovation.
Daily change in the price of a broad market stock, index - GURU.Markets
Simulations Plus is a leading provider of modeling and simulation software for pharmaceutical research. Its business serves as a barometer of global scientific activity. The chart below illustrates general market fluctuations, which can be used to assess the stability of Simulations Plus.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Simulations Plus Inc.
The year-over-year performance of Simulations Plus, Inc. is a story of digitalization in the pharmaceutical industry. The 12-month market capitalization growth of this clinical trial simulation software company reflects demand from pharmaceutical companies, who are increasingly using its tools to speed up and reduce the cost of developing new drugs.
Annual dynamics of market capitalization of the market segment - It med
Simulations Plus, Inc. provides simulation software used by pharmaceutical companies to accelerate drug development. This chart shows how its key role in R&D, subscription model, and rising drug development costs are driving its rapid growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Simulations Plus, with its drug development modeling software, is a gold mine for biotech. Demand for its services isn't dependent on the economy, but rather driven by pharmaceutical companies' R&D budgets. The company's stock price reflects the long-term trend toward faster and cheaper drug development.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Simulations Plus Inc.
The performance of Simulations Plus, a pharmaceutical software provider, depends on R&D cycles. The monthly fluctuations on the chart reflect demand for its simulation software, which helps pharmaceutical companies accelerate drug development, ensuring stable growth.
Monthly dynamics of market capitalization of the market segment - It med
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate drug development. The company's growth depends on the integration of its software into R&D processes. The dynamics of the medical IT sector reflect the trend toward using data and AI to improve efficiency, a key focus for Simulations Plus.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Simulations Plus develops modeling software for the pharmaceutical industry. Its clients are large pharmaceutical companies that ensure stable demand. The company's shares combine characteristics of the technology and medical sectors, which contributes to their stability. Their performance often depends on product news rather than the overall market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Simulations Plus Inc.
Simulations Plus provides modeling software for pharmaceutical research, helping to predict drug performance. Its weekly stock price reflects pharmaceutical companies' R&D spending and the trend toward using computer modeling to accelerate drug development.
Weekly dynamics of market capitalization of the market segment - It med
Pharmaceutical simulation software companies like Simulations Plus are benefiting from the overall trend toward accelerated R&D. The chart below illustrates the dynamics of this growing segment. It allows us to assess how Simulations Plus's leadership position is helping it grow faster and be more profitable than its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Simulations Plus creates modeling software used in pharmaceutical research to predict drug properties. Its software helps save time and money. The chart shows how the company's stock, thanks to its niche, can be more resilient to general market downturns.
Market capitalization of the company, segment and market as a whole
SLP - Market capitalization of the company Simulations Plus Inc.
The Simulations Plus market capitalization chart reflects investors' valuation of its pharmaceutical modeling software. Its dynamics reflect the growing use of computer modeling to predict drug properties, which accelerates and reduces the cost of drug development. The company's scale speaks to its status as a leader in this narrow but important IT niche.
SLP - Share of the company's market capitalization Simulations Plus Inc. within the market segment - It med
Simulations Plus provides modeling and simulation software for pharmaceutical research, helping to predict how drugs will behave in the body. Its market share in the medical IT sector reflects its key role in reducing the cost and accelerating drug development. The company's importance is growing as in silico methods become the standard in R&D.
Market capitalization of the market segment - It med
This graph shows the total value of the entire medical IT sector. For Simulations Plus, whose software models drug performance, this line is a map of the future of pharmaceuticals. The rising graph reflects how computer modeling (in silico) is becoming an integral part of drug development, reducing costs and accelerating the process—the company's core business.
Market capitalization of all companies included in a broad market index - GURU.Markets
Simulations Plus creates modeling software used in the pharmaceutical industry to predict drug properties. Its market capitalization is the value of its "digital trials." This represents the market share of technologies that accelerate and reduce the cost of drug development.
Book value capitalization of the company, segment and market as a whole
SLP - Book value capitalization of the company Simulations Plus Inc.
Simulations Plus creates simulation software for the pharmaceutical industry. Its book value is its intellectual and financial capital. It reflects the value of the software developed and the cash reserves for further innovation. How strong was this knowledge-intensive foundation? The chart below will show.
SLP - Share of the company's book capitalization Simulations Plus Inc. within the market segment - It med
Simulations Plus, Inc. creates software for the pharmaceutical industry, but its operations require computing power. Its physical assets are not factories, but server clusters and offices where complex simulation software is developed and supported. The chart shows its share of the physical IT infrastructure supporting drug development.
Market segment balance sheet capitalization - It med
Simulations Plus, a developer of simulation software for the pharmaceutical industry, has a very lightweight business. Its assets are code and scientific models. The BCap_Seg chart for the IT sector looks modest, confirming that value is created here through intelligence, not factories.
Book value of all companies included in the broad market index - GURU.Markets
Simulations Plus' assets are not laboratories, but a portfolio of software for modeling and simulation in pharmaceutical research, which helps reduce drug development costs. Its capital is intellectual property. The chart below shows how this digital R&D tool stacks up against the biotech landscape.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Simulations Plus Inc.
Simulations Plus' balance sheet is its intellectual property. The huge award is a recognition of its software, which allows pharmaceutical companies to save billions of dollars by simulating clinical trials on a computer. The graph is a reward for the "digital revolution" in R&D.
Market to book capitalization ratio in a market segment - It med
Simulations Plus develops modeling software used in the pharmaceutical industry to predict drug properties. Its value lies in its software and scientific models. The chart shows the high premium the market pays for its key role in reducing the cost and speed of drug development.
Market to book capitalization ratio for the market as a whole
Simulations Plus provides modeling and simulation software for pharmaceutical research. Its core asset is its science-intensive software that accelerates drug development. This chart illustrates the significant premium the market pays for its intellectual property and key role in R&D.
Debts of the company, segment and market as a whole
SLP - Company debts Simulations Plus Inc.
Simulations Plus, a developer of simulation software for the pharmaceutical industry, is growing through acquisitions and organic development. Debt is used to finance these M&A deals. This chart shows how the company is using leverage to consolidate its niche, striving to become a key technology partner for pharmaceutical R&D departments.
Market segment debts - It med
Simulations Plus provides modeling and simulation software used in pharmaceutical research to predict drug properties. It's a niche B2B software company. Debt can be used for acquisitions. This chart shows how conservative or aggressive the company's financial policy is in its scientific niche.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Simulations Plus Inc.
Simulations Plus creates software for pharmaceutical modeling, helping to accelerate drug development. Debt can be used for R&D or acquisitions. This chart shows how an IT company with a strong market position finances its growth. It helps assess whether its stable revenues allow it to comfortably service its debt.
Market segment debt to market segment book capitalization - It med
Simulations Plus develops modeling software used by pharmaceutical companies to predict drug properties, accelerating their development. The chart illustrates the company's debt strategy in the IT sector, providing context for how Simulations Plus finances its unique R&D in pharma technologies.
Debt to book value of all companies in the market
Simulations Plus, Inc. creates pharmaceutical modeling software that helps reduce drug development costs. Its business model is software-based, not asset-heavy. This chart shows the overall debt load in the market. It helps assess how an asset-light company can maintain low debt levels, compared to its clients in the capital-intensive pharmaceutical industry.
P/E of the company, segment and market as a whole
P/E - Simulations Plus Inc.
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate drug development. This chart shows how the market perceives its role in R&D digitalization. High values reflect the growing adoption of computer modeling to reduce costs and risks in the pharmaceutical industry.
P/E of the market segment - It med
Simulations Plus is a leader in pharmaceutical simulation software. This chart shows the average rating for the software sector. It shows the premium the market places on Simulations Plus for its unique niche and the critical importance of its products for accelerating drug development.
P/E of the market as a whole
Simulations Plus, Inc. provides software and consulting services for modeling and simulation in pharmaceutical research, helping to accelerate drug development. This chart shows the overall level of optimism in the technology and pharmaceutical sectors. It helps determine whether SLP is valued as a unique technology partner for the pharmaceutical industry or whether its value follows general trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Simulations Plus Inc.
Simulations Plus develops simulation software used by pharmaceutical companies to accelerate drug development. Future profits depend on R&D spending in the pharmaceutical industry. This chart shows market expectations for the increased use of computer simulation in drug development.
%20P%2FE%20Simulations%20Plus%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Simulations-Plus-Inc.&v=1772513400233 "Chart of the company's future (projected) P/E Simulations Plus Inc.")
Future (projected) P/E of the market segment - It med
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to predict how drugs will behave in the human body. This chart reflects the company's future profitability expectations, indicating whether analysts believe its technologies will become the standard in drug development.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-It-med&v=1772513400242 "Future (projected) P/E graph of the market segment - It med")
Future (projected) P/E of the market as a whole
Simulations Plus develops modeling software used by pharmaceutical companies to accelerate drug development. This chart of overall market expectations reflects their belief in the digitalization of R&D. The company's products help reduce costs, which is valuable in any market situation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513400271 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Simulations Plus Inc.
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate drug development. This chart shows how the company profits from R&D digitalization. Revenue growth depends on the implementation of its software, which helps reduce the costs and risks of clinical trials.
Profit of companies in the market segment - It med
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate drug development. Its business benefits from the pharmaceutical industry's desire to reduce research costs and time. The company's profitability reflects the trend toward digitalization and the use of AI in pharmaceuticals.
Overall market profit
Simulations Plus develops modeling software used by pharmaceutical companies to accelerate drug development. Demand for its products depends on R&D budgets in the pharmaceutical industry. This graph, reflecting corporate profitability, influences the willingness of biotech and pharmaceutical companies to invest in advanced tools to improve research efficiency.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Simulations Plus Inc.
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate drug development. This chart reflects analysts' expectations for future revenue. This forecast is supported by the growing adoption of in silico technologies to reduce costs and risks in R&D.
%20profit%20of%20the%20company%20Simulations%20Plus%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Simulations-Plus-Inc.&v=1772513400343 "Graph of future (projected) profit of the company Simulations Plus Inc.")
Future (predicted) profit of companies in the market segment - It med
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate drug development. The profitability forecasts for the sector, shown in the graph, reflect the company's commitment to efficiency in R&D. This chart helps evaluate how Simulations Plus tools help reduce costs and risks in the pharmaceutical industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-It-med&v=1772513400351 "Graph of future (predicted) profits of companies in a market segment - It med")
Future (predicted) profit of the market as a whole
Simulations Plus develops modeling and simulation software used in the pharmaceutical industry to accelerate drug development. R&D spending in the pharmaceutical industry is relatively stable, but the overall positive economic climate, reflected in this chart, is stimulating investment in innovative tools to improve efficiency.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513400358 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Simulations Plus Inc.
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate drug development. This chart shows the premium investors are paying for its revenue. This high valuation reflects the key role its software plays in reducing the costs and risks of developing new drugs.
P/S market segment - It med
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate and reduce the cost of drug development. This metric reflects the average revenue estimate for the software sector and helps understand the market premium for unique software that has become a standard in the pharmaceutical industry.
P/S of the market as a whole
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate drug development. The company's technologies help predict how drugs will react in the body. The graph below compares how the market values the revenue of a niche IT company in the pharmaceutical industry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Simulations Plus Inc.
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate drug development. This chart shows investors' high estimates for its future revenue. This estimate reflects the growing adoption of its R&D cost-cutting tools.
%20P%2FS%20Simulations%20Plus%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Simulations-Plus-Inc.&v=1772513400396 "The graph of the company's future (projected) P/S Simulations Plus Inc.")
Future (projected) P/S of the market segment - It med
Simulations Plus develops modeling and simulation software used in pharmaceutical research to predict drug properties. This chart compares the company's estimated future sales with other medical IT companies. It reflects investor expectations for the growing use of computer modeling to accelerate drug development.
%20P%2FS%20market%20segment%20graph%20-%20It%20med&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-It-med&v=1772513400419 "Future (projected) P/S market segment graph - It med")
Future (projected) P/S of the market as a whole
Simulations Plus provides modeling and simulation software used in pharmaceutical research to predict drug properties. Its growth is driven by R&D spending in the pharmaceutical industry. This overall forecast is important for the company, as economic growth allows pharmaceutical companies to invest more in technologies that accelerate drug development.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513400444 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Simulations Plus Inc.
This chart shows the revenue of Simulations Plus, a company that develops modeling and simulation software for pharmaceutical research. Its software helps predict how drugs will behave in the body, speeding up and reducing the cost of development. Revenue growth reflects the growing adoption of computer modeling in pharmaceutical R&D processes.
Sales of companies in the market segment - It med
Simulations Plus is a leading provider of modeling and simulation software for pharmaceutical research. Its software helps predict how drugs will behave in the body. This chart shows revenue in the medical IT sector. It reflects the trend toward using computer modeling to speed up and reduce the cost of drug development, which is the core value of the company's products.
Overall market sales
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate drug development. Demand for its products depends on R&D spending in the pharmaceutical industry. This trend in general economic activity indirectly impacts Simulations Plus, as economic growth ensures budget stability for its clients.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Simulations Plus Inc.
Simulations Plus provides modeling and simulation software used by pharmaceutical companies to accelerate drug development. This projected revenue chart reflects R&D spending in the pharmaceutical industry. The increase is driven by expectations of increased demand for its tools, which help reduce costs and risks in the development of new drugs.
%20sales%20of%20the%20company%20Simulations%20Plus%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Simulations-Plus-Inc.&v=1772513400524 "Schedule of future (projected) sales of the company Simulations Plus Inc.")
Future (projected) sales of companies in the market segment - It med
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to predict drug properties, speeding up and reducing the cost of drug development. This graph shows projected revenues for the entire healthcare IT sector, reflecting the growing adoption of computer modeling in the pharmaceutical industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-It-med&v=1772513400567 "Schedule of future (projected) sales of companies in the market segment - It med")
Future (projected) sales of the market as a whole
Simulations Plus develops software for modeling in pharmaceutical research, helping to accelerate drug development. Demand for its products depends on R&D budgets at pharmaceutical companies. Stable economic growth ensures the sustainability of these budgets and stimulates investment in technologies that improve research efficiency.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513400582 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Simulations Plus Inc.
Simulations Plus develops simulation software used by pharmaceutical companies to accelerate drug development. It's a high-margin business. The chart shows how software license sales and consulting services generate stable and high profitability, typical of niche IT companies.
Market segment marginality - It med
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate and reduce the cost of drug development. This chart shows the profitability of its SaaS and consulting models. Its leadership in its niche and the indispensability of its tools in the R&D process allow the company to maintain exceptionally high margins.
Market marginality as a whole
Simulations Plus provides modeling and simulation software used by pharmaceutical companies to accelerate drug development. This overall economic return impacts their clients' R&D budgets. However, the trend toward increased drug development efficiency is a long-term driver supporting demand for their software.
Employees in the company, segment and market as a whole
Number of employees in the company Simulations Plus Inc.
Simulations Plus develops modeling software used by pharmaceutical companies to predict drug properties, accelerating their development. This graph shows the team of scientists and programmers. The growth of the team reflects the increasing adoption of modeling technologies in pharmaceutical R&D processes.
Share of the company's employees Simulations Plus Inc. within the market segment - It med
Simulations Plus develops modeling and simulation software used by pharmaceutical companies to accelerate drug development. Its core asset is its team of scientists and programmers. This metric reflects its intellectual prowess, demonstrating the proportion of highly specialized talent at the intersection of pharmaceuticals and IT it attracts.
Number of employees in the market segment - It med
Simulations Plus develops modeling software used by pharmaceutical companies to predict how drugs will behave in the human body. This graph shows how IT is accelerating drug development. The growth in the number of software scientists reflects the pharmaceutical industry's desire to reduce the costs and time of clinical trials.
Number of employees in the market as a whole
Simulations Plus develops modeling and simulation software used in the pharmaceutical industry to accelerate drug development. Its growing staff of scientists and programmers reflects the trend toward digitalization of R&D. This chart shows how IT companies serving knowledge-intensive industries are creating unique jobs at the intersection of technology and science.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Simulations Plus Inc. (SLP)
Simulations Plus provides modeling and simulation software used by pharmaceutical companies to accelerate drug development. It's a knowledge-intensive IT business. This chart shows a very high cost per employee. The market values the company's intellectual capital, its software, and its unique expertise at the intersection of pharmaceuticals and IT.
%20of%20the%20company%20Simulations%20Plus%20Inc.%20(SLP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Simulations-Plus-Inc.-SLP&v=1772513400852 "Chart of market capitalization per employee (in thousands of dollars) of the company Simulations Plus Inc. (SLP)")
Market capitalization per employee (in thousands of dollars) in the market segment - It med
Simulations Plus develops simulation software for the pharmaceutical industry, helping to accelerate drug development. This metric reflects the value of their intellectual property. Their high capitalization per employee demonstrates that their small team of scientists and programmers is creating a high-margin product that is in demand worldwide.
%20by%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-It-med&v=1772513400862 "Market capitalization per employee (in thousands of dollars) by market segment - It med")
Market capitalization per employee (in thousands of dollars) for the overall market
Simulations Plus develops software for modeling and simulation in pharmaceutical research. This metric demonstrates how niche software creates enormous value. The company's products help accelerate drug development, making them indispensable for clients and ensuring high market valuation for its team's contributions.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513400883 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Simulations Plus Inc. (SLP)
Simulations Plus is a unique company. They create simulation software that helps pharmaceutical companies predict how drugs will behave in the body (ADMET). They are a SaaS/software business. This graph shows the value of their software. Their high profit per employee is a result of selling high-margin software that accelerates R&D for others.
%20Chart%20Simulations%20Plus%20Inc.%20(SLP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Simulations-Plus-Inc.-SLP&v=1772513400887 "Company Profit Per Employee (in thousands of dollars) Chart Simulations Plus Inc. (SLP)")
Profit per employee (in thousands of dollars) in the market segment - It med
Simulations Plus provides modeling software and consulting services for the pharmaceutical industry, helping to predict drug performance. It's a high-margin, science-intensive business. This metric should be high, reflecting the value that a small team of scientists and developers creates for its R&D clients.
%20in%20the%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-It-med&v=1772513400898 "Chart of profit per employee (in thousands of dollars) in the market segment - It med")
Profit per employee (in thousands of dollars) for the market as a whole
Simulations Plus provides software and consulting services for pharmaceutical industry modeling (for example, how a drug will behave in the body). It's a high-margin, IP-based business. This chart shows how efficiently their team of scientists and software developers creates and markets products that save pharmaceutical companies billions.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513400921 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Simulations Plus Inc. (SLP)
Simulations Plus provides modeling and simulation software for pharmaceutical research. This chart shows how the company monetizes its research-intensive products. The growth in revenue per employee reflects the adoption of their software by major pharmaceutical companies to accelerate drug development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Simulations-Plus-Inc.-SLP&v=1772513400936 "Sales chart per company employee Simulations Plus Inc. (SLP)")
Sales per employee in the market segment - It med
Simulations Plus (SLP) is a leading developer of in silico modeling and simulation software used by pharmaceutical companies to predict drug properties (pharmacokinetics). This chart shows the revenue (from software and consulting) generated by each employee (scientist, programmer). This is an indicator of the value of their science-intensive software for accelerating pharmaceutical R&D.
Sales per employee for the market as a whole
Simulations Plus is a company that develops in silico modeling and simulation software used by pharmaceutical companies to predict drug properties, accelerating R&D. It's a B2B SaaS business. This metric reflects how effectively they license their high-margin software and consulting services, monetizing the work of their scientists.
Short shares by company, segment and market as a whole
Shares shorted by company Simulations Plus Inc. (SLP)
Simulations Plus provides modeling software that helps pharmaceutical companies predict how a drug will behave in the body. This chart highlights bearish bets. Bears can expect a decline in biotech funding to lead to cuts in R&D budgets and, consequently, software purchases.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Simulations-Plus-Inc.-SLP&v=1772513400986 "Short Shares Chart for the Company Simulations Plus Inc. (SLP)")
Shares shorted by market segment - It med
Simulations Plus provides modeling and simulation software used by pharmaceutical companies in drug development (to predict how a drug will perform). This indicator reflects skepticism. "Shorts" here are bets that pharma and biotech companies will cut their R&D budgets.
Shares shorted by the overall market
Simulations Plus provides modeling and simulation software for the pharmaceutical industry, helping to accelerate drug development. This chart illustrates the general market fear. Pharmaceutical IT is a growing sector. But when the market panics, investors may fear that even large pharmaceutical companies will begin cutting R&D and software budgets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Simulations Plus Inc. (SLP)
Simulations Plus (SLP) is a software company. They create in silico modeling and simulation programs that pharmaceutical companies use for R&D, predicting how drugs will react in the body. This chart measures momentum. It shows "overheating" (above 70) amid strong demand from pharma, or "overselling" (below 30) amid slowing R&D budgets.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Simulations-Plus-Inc.-SLP&v=1772513401032 "RSI 14 indicator chart for the company's stock Simulations Plus Inc. (SLP)")
RSI 14 Market Segment - It med
Simulations Plus (SLP) — "biosimulation" (like Certara). Their software (GastroPlus) allows pharmaceutical companies to *simulate* drug trials on a computer. RSI_14_Seg for "It med" (medical IT) shows the "temperature" in the sector. It helps us understand: is SLP's growth due to their "sticky" SaaS or the general "overheating" of the biotech software sector?
RSI 14 for the overall market
Simulations Plus (SLP) provides simulation software for the pharmaceutical industry. This chart is an indicator of R&D budgets in the pharmaceutical industry. In the euphoria of biotech, funding is generous and spent on SLP software to accelerate R&D. In a panic, the funding for biotech is turned off, and budgets for "auxiliary" software are cut.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SLP (Simulations Plus Inc.)
Simulations Plus (SLP) is a leading provider of pharmacokinetic/pharmacodynamic modeling software that helps pharmaceutical companies predict drug performance. This chart shows the average 12-month forecast. It reflects analyst expectations for growth in biotech R&D budgets and the adoption of in silico modeling.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SLP-Simulations-Plus-Inc.&v=1772513401057 "A chart showing analyst consensus forecasts for the expected stock price. SLP (Simulations Plus Inc.)")
The difference between the consensus estimate and the actual stock price SLP (Simulations Plus Inc.)
Simulations Plus is a unique scientific SaaS company. They create modeling and simulation (M&S) software. Pharmaceutical companies use their software to computer-generated predict how drugs will act in the human body *before* actual clinical trials begin. This chart shows how much analysts believe in their key role in accelerating pharmaceutical R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SLP-Simulations-Plus-Inc.&v=1772513401070 "A chart showing the difference between the consensus forecast and the actual stock price. SLP (Simulations Plus Inc.)")
Analyst consensus forecast for stock prices by market segment - It med
Simulations Plus (SLP) is a leader in drug development modeling. Its software (GastroPlus) allows pharmaceutical companies to virtually test how a drug will behave in the body. This chart shows general expectations for the medical IT sector. It reflects whether experts believe biosimulation will grow to save money on R&D.
Analysts' consensus forecast for the overall market share price
Simulations Plus (SLP) is a company that digitalizes drug development. Their software (GastroPlus, DILIsym) simulates how drugs behave in the body, saving pharmaceutical companies millions in R&D costs. This chart shows the overall risk appetite. It reflects the level of confidence analysts place in Big Pharma's R&D budgets and their willingness to invest in IT.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Simulations Plus Inc.
Simulations Plus is a SaaS service for R&D. Their simulation software (GastroPlus, DILIsym) allows pharmaceutical companies to test drugs virtually (in silico) before expensive clinical trials. This chart is a barometer of their sticky niche. It likely reflects their annual recurring revenue (ARR) and their ability to sell their essential software to R&D departments worldwide.
AKIMA Market Segment Index - It med
Simulations Plus (SLP) is a SaaS leader in biosimulation (like Certara); the company provides business-to-business (B2B) software for pharmaceutical companies that enables computer-aided drug modeling (CDP). This aggregate metric evaluates companies. The graph shows the average value for the software segment. This benchmark provides insight into how this essential (R&D) SaaS model (SLP) differentiates it from the average competitor.
The AKIM Index for the overall market
Simulations Plus is a leader in modeling and simulation (M&S) software for the pharmaceutical industry. It helps predict drug properties, accelerating R&D. This chart, reflecting the market average, is a backdrop. It helps assess how this high-margin IT business, integrated into drug development, compares against the backdrop of general macroeconomic fluctuations.
